| abstract |
The present invention relates to 11β- (4-acetylphenyl) -17β-hydroxy-17α- (1,1,2,2,2-pentafluoroethyl) -estradi-4,9-diene—a progesterone receptor antagonist. Relating to the combination of 3-one, or a pharmaceutically acceptable derivative or analog thereof, and at least one lutein hormone releasing hormone agonist or antagonist, and for the prevention and treatment of BRCA1- or 2-mediated diseases Of the combination. Lutein hormone that can be combined with the compound 11β- (4-acetylphenyl) -17β-hydroxy-17α- (1,1,2,2,2-pentafluoroethyl) -estradi-4,9-dien-3-one Release hormone agonists and antagonists are, for example, gonadorelin, goserelin, triptorelin, buserelin, nafarelin, deslorelin, histrelin, antide, ramorelix, cetrorelix, antarelix, ORG30850, abarelix, ganirelix, and leuproline. |